TwinBeech Capital’s ARS Pharmaceuticals SPRY Stock Holding History

TwinBeech Capital’s Portfolio SPRY Stock Details SPRY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-21,700	Closed	-$273K	–	957
2025 Q1	$273K	Buy	+21,700	New	+$261K	0.01%	629

Other funds holding SPRY

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SOCM

SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

TwinBeech Capital's SPRY Position: Q2 2025 in Review

TwinBeech Capital sold out of ARS Pharmaceuticals (SPRY) in Q2 2025, closing a stake of 21,700 shares — an estimated $273K sold.

TwinBeech Capital first reported a position in SPRY in Q1 2025 and held it in 1 quarter. The position peaked at $273K in Q1 2025. 187 funds tracked by Wall St. Rank hold SPRY as of Q2 2025.

TwinBeech Capital reported no remaining ARS Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
TwinBeech Capital sold 21,700 ARS Pharmaceuticals shares in Q2 2025, an estimated $273K.
TwinBeech Capital first reported a position in ARS Pharmaceuticals in Q1 2025 and held it in 1 quarter.
TwinBeech Capital's ARS Pharmaceuticals position peaked at $273K in Q1 2025.
187 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q2 2025.

Based on TwinBeech Capital's 13F filing for Q2 2025, filed 14 Aug 2025.